Niagen Bioscience reported a net loss of $1.2 million for the third quarter of 2026, a significant decline from a $4.6 million profit in the prior year, driven by a 20% decrease in net sales. However, for the nine-month period, the company remained profitable with a net income of $6.1 million, bolstered by a $4.8 million gain from the sale of an operating segment.
Niagen Bioscience reported Q3 2026 net sales of $27.2 million and a net loss of $1.2 million, while generating $2.6 million in operating cash flow. The company launched several new products including Niagen NanoCloud topical and an at-home injection kit, while expanding retail distribution through Walmart.com, GNC, and Sam's Club.
Term
Q3 2026
“During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform. We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research. As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond.”